Increased T-cell receptor clonality and novel clonotypes seen with intismeran plus pembrolizumab versus pembrolizumab alone.
Zaynich is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.